Switch theme
Sign up to access all valuation multiples
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
2003
2.2K+
LTM Revenue $2.5B
LTM EBITDA $165M
$38.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alnylam Pharmaceuticals has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $165M.
In the most recent fiscal year, Alnylam Pharmaceuticals achieved revenue of $2.2B and an EBITDA of -$179M.
Alnylam Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alnylam Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Profit | $2.1B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $165M | XXX | -$179M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -8% | XXX | XXX | XXX |
| EBIT | -$99.6M | XXX | -$177M | XXX | XXX | XXX |
| EBIT Margin | -4% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | -$214M | XXX | -$278M | XXX | XXX | XXX |
| Net Margin | -9% | XXX | -12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $58.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alnylam Pharmaceuticals's stock price is $305.
Alnylam Pharmaceuticals has current market cap of $39.7B, and EV of $38.4B.
See Alnylam Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $38.4B | $39.7B | XXX | XXX | XXX | XXX | $-1.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alnylam Pharmaceuticals has market cap of $39.7B and EV of $38.4B.
Alnylam Pharmaceuticals's trades at 17.1x EV/Revenue multiple, and -214.6x EV/EBITDA.
Equity research analysts estimate Alnylam Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alnylam Pharmaceuticals has a P/E ratio of -185.7x.
See valuation multiples for Alnylam Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39.7B | XXX | $39.7B | XXX | XXX | XXX |
| EV (current) | $38.4B | XXX | $38.4B | XXX | XXX | XXX |
| EV/Revenue | 15.3x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBITDA | 232.0x | XXX | -214.6x | XXX | XXX | XXX |
| EV/EBIT | -385.2x | XXX | -217.0x | XXX | XXX | XXX |
| EV/Gross Profit | 18.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -185.7x | XXX | -142.8x | XXX | XXX | XXX |
| EV/FCF | -5842.3x | XXX | -901.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlnylam Pharmaceuticals's last 12 month revenue growth is 29%
Alnylam Pharmaceuticals's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.9M for the same period.
Alnylam Pharmaceuticals's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alnylam Pharmaceuticals's rule of X is 80% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alnylam Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -8% | XXX | XXX | XXX |
| EBITDA Growth | 166% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 93% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alnylam Pharmaceuticals acquired XXX companies to date.
Last acquisition by Alnylam Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Alnylam Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alnylam Pharmaceuticals founded? | Alnylam Pharmaceuticals was founded in 2003. |
| Where is Alnylam Pharmaceuticals headquartered? | Alnylam Pharmaceuticals is headquartered in United States of America. |
| How many employees does Alnylam Pharmaceuticals have? | As of today, Alnylam Pharmaceuticals has 2.2K+ employees. |
| Who is the CEO of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's CEO is Dr. Yvonne L Greenstreet, MB.Ch.B.. |
| Is Alnylam Pharmaceuticals publicy listed? | Yes, Alnylam Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals trades under ALNY ticker. |
| When did Alnylam Pharmaceuticals go public? | Alnylam Pharmaceuticals went public in 2004. |
| Who are competitors of Alnylam Pharmaceuticals? | Similar companies to Alnylam Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's current market cap is $39.7B |
| What is the current revenue of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Alnylam Pharmaceuticals? | Current revenue multiple of Alnylam Pharmaceuticals is 15.3x. |
| Is Alnylam Pharmaceuticals profitable? | Yes, Alnylam Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's last 12 months EBITDA is $165M. |
| What is Alnylam Pharmaceuticals's EBITDA margin? | Alnylam Pharmaceuticals's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Alnylam Pharmaceuticals? | Current EBITDA multiple of Alnylam Pharmaceuticals is 232.0x. |
| What is the current FCF of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's last 12 months FCF is -$6.6M. |
| What is Alnylam Pharmaceuticals's FCF margin? | Alnylam Pharmaceuticals's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Alnylam Pharmaceuticals? | Current FCF multiple of Alnylam Pharmaceuticals is -5842.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
